Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.
Lei X, de Groot DC, Welters MJP, de Wit T, Schrama E, van Eenennaam H, Santegoets SJ, Oosenbrug T, van der Veen A, Vos JL, Zuur CL, de Miranda NFCC, Jacobs H, van der Burg SH, Borst J, Xiao Y. Lei X, et al. Among authors: van der burg sh. Cell Mol Immunol. 2024 Apr;21(4):374-392. doi: 10.1038/s41423-024-01133-1. Epub 2024 Feb 21. Cell Mol Immunol. 2024. PMID: 38383773 Free PMC article.
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, Franken KL, Drijfhout JW, Fleuren GJ, Kenter G, Melief CJ, Offringa R, van der Burg SH. Welters MJ, et al. Among authors: van den eeden sj, van der hulst jm, van der burg sh. Cancer Res. 2003 Feb 1;63(3):636-41. Cancer Res. 2003. PMID: 12566307
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
Welters MJ, Filippov DV, van den Eeden SJ, Franken KL, Nouta J, Valentijn AR, van der Marel GA, Overkleeft HS, Lipford G, Offringa R, Melief CJ, van Boom JH, van der Burg SH, Drijfhout JW. Welters MJ, et al. Among authors: van boom jh, van den eeden sj, van der marel ga, van der burg sh. Vaccine. 2004 Dec 2;23(3):305-11. doi: 10.1016/j.vaccine.2004.06.008. Vaccine. 2004. PMID: 15530672
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens.
van der Burg SH, Piersma SJ, de Jong A, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R. van der Burg SH, et al. Among authors: van den hende m, van rood jj, van der hulst jm. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12087-92. doi: 10.1073/pnas.0704672104. Epub 2007 Jul 5. Proc Natl Acad Sci U S A. 2007. PMID: 17615234 Free PMC article.
Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.
Piersma SJ, Welters MJ, van der Hulst JM, Kloth JN, Kwappenberg KM, Trimbos BJ, Melief CJ, Hellebrekers BW, Fleuren GJ, Kenter GG, Offringa R, van der Burg SH. Piersma SJ, et al. Among authors: van der hulst jm, van der burg sh. Int J Cancer. 2008 Feb 1;122(3):486-94. doi: 10.1002/ijc.23162. Int J Cancer. 2008. PMID: 17955486
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ. Kenter GG, et al. Among authors: van der burg sh. Clin Cancer Res. 2008 Jan 1;14(1):169-77. doi: 10.1158/1078-0432.CCR-07-1881. Clin Cancer Res. 2008. PMID: 18172268 Free article. Clinical Trial.
348 results